Entrada Therapeutics Reports 96% Revenue Drop, Widened $40M Q1 Loss
TRDA has more than doubled off its 52-week low of $4.93 on elevated volume (2.0× avg).
Summary
Entrada Therapeutics reported Q1 2026 revenue of $875K, representing a significant 95.7% year-over-year decline, alongside a net loss of $39.72 million, which widened by 128.9% compared to the prior year. Diluted EPS was ($0.95). This financial update, reflecting lower collaboration revenue and increased operating expenses, follows the company's announcement earlier today of positive topline results from its Phase 1/2 ELEVATE-44-201 study for ENTR-601. While losses are anticipated for a clinical-stage biotech, the substantial revenue decline and widening net loss are material, indicating increased cash burn as the company advances its pipeline. Investors will closely monitor the company's cash runway, which is projected to fund operations into Q3 2027, and upcoming clinical milestones, including results from the Vertex collaboration in H2 2026.
At the time of this announcement, TRDA was trading at $11.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $622.3M. The 52-week trading range was $4.93 to $16.45. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.